Does Metformin potentiate the effect of Rosuvastatin therapy on biochemical markers in Patients with Polycystic Ovary Syndrome?
- Conditions
- Polycystic ovary syndrome (PCOS)Reproductive Health and Childbirth - Other reproductive health and childbirth disorders
- Registration Number
- ACTRN12612000663853
- Lead Sponsor
- American University of Beirut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 54
adult females aged 18-55, diagnosed as having PCOS, not planning to conceive
patients with cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, adrenal hyperplesia, androgen secretingtumors or other endocrinopathies, cancer, kidney or liver disease, and smokers. Patients who have also been treated with hormone medications or any other medication that could interfere with ovarian function, insulin sensitivity and lipid profile within the 3 months prior to their entry into the study are also be excluded. Moreover, since the effect of metformin may be less in subjects with a mean BMI of > 34 kg/m2 and thus pose as a limitation to the study results, patients with a BMI of >34 kg/m2 will be excluded from participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change in inflammatory markers in PCOS patients on Resuvastatin if Metformin is added. this is tested by serum assay every 3 months[baseline (0 months), 3 months, and 6 months]
- Secondary Outcome Measures
Name Time Method menstrual irregularities are assessed every month where the patients keep daily menstrual diary to report it every month.[0 month ,3 months ,6 months]